Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDefinium Therapeutics, Inc.

Definium Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
34.575 USD 1.30 ( 3.92%)
Last update at 2026-11-09T15:34:00Z
VOLUME
221741
Market Cap
2311.00M

Momentum Score

…

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
33.35
Low
34.67
High
52 Week Price Range
6.03
Low
26.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Definium Therapeutics, Inc. is a NASDAQ-listed biotechnology company; publicly available disclosures provide limited detail on its pipeline and commercial strategy. As a clinical-stage biopharma, long-term growth may be driven by successful clinical trial results, regulatory approvals and strategic partnerships, a profile that may attract investors seeking exposure to potential upside from therapeutic development.

The most important investment risks are clinical and regulatory failure, the need for ongoing financing leading to dilution, and operational and market volatility common to early-stage biotech ventures, which investors should monitor.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
33.27
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.09
ROE
-64.06%
Net Debt
-257.84M
ROCE
-44.54%
Diluted EPS TTM
-2.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -183.79M -108.68M -95.73M -56.80M -94.19M
Net income -183.79M -108.68M -95.73M -56.80M -93.04M
Selling general administrative 48.64M 38.62M 41.74M 30.16M 59.06M
Gross profit - -0.53M -3.16M - -
Reconciled depreciation 0.00M 0.53M 3.16M 3.18M 2.62M
Ebit - -106.40M -95.73M -66.33M -93.85M
Ebitda -178.31M -105.87M -92.57M -63.15M -91.24M
Depreciation and amortization - 0.53M 3.16M 3.18M 2.62M
Operating income -166.31M -103.92M -93.87M -66.33M -93.85M
Other operating expenses 166.31M 103.92M 93.87M 66.33M 93.85M
Interest expense 5.48M 2.28M 0.92M 1.50M 0.36M
Tax provision - - - 0.00M -1.16M
Interest income 10.96M 11.56M 5.58M - -
Net interest income 5.48M 9.28M 4.66M 1.50M -0.36M
Income tax expense - - - - -1.16M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 166.31M 103.39M 90.70M 66.33M 93.85M
Cost of revenue - 0.53M 3.16M - -
Total other income expense net -17.48M -4.76M -1.87M 9.54M -0.34M
Net income from continuing ops -183.79M -108.68M -95.73M -56.80M -93.04M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 440.10M 302.15M 124.54M 169.99M 164.00M
Intangible assets - - 0.53M 3.69M 6.87M
Other current assets 7.73M 7.88M 4.17M 3.91M 3.68M
Total liab 107.77M 60.70M 46.41M 19.08M 12.34M
Total stockholder equity 332.33M 241.45M 78.13M 150.92M 151.66M
Other current liab 61.35M 36.84M 28.11M 15.71M 6.23M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -582.67M -398.88M -290.20M -194.47M -137.67M
Good will 19.92M 19.92M 19.92M 19.92M 19.92M
Cash 257.84M 273.74M 99.70M 142.14M 133.54M
Total current liabilities 66.70M 38.85M 32.25M 17.89M 10.41M
Net debt -257.84M -251.89M -85.58M -142.07M -133.54M
Short term debt - - - 0.07M -
Short long term debt total - 21.85M 14.13M 0.07M -
Other stockholder equity 913.91M 639.51M 367.99M 344.76M 288.29M
Total current assets 419.32M 281.62M 103.87M 146.06M 137.22M
Short term investments 153.76M 0.00M - - -
Long term debt 40.58M 21.85M 14.13M - -
Accounts payable 5.35M 2.01M 4.14M 2.11M 4.18M
Accumulated other comprehensive income 1.08M 0.82M 0.34M 0.63M 1.05M
Non currrent assets other 0.86M 0.61M 0.22M 0.33M -
Non current assets total 20.78M 20.53M 20.67M 23.94M 26.79M
Capital lease obligations - - - 0.07M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -151.61M 0.00M - - -
Total cashflows from investing activities -151.61M - - - -0.30M
Net borrowings 20.00M 10.86M 21.68M 0.00M -
Total cash from financing activities 267.27M 253.20M 21.85M 59.05M 98.82M
Net income -183.79M -108.68M -95.73M -56.80M -93.04M
Change in cash -15.90M 174.04M -42.44M 8.60M 53.45M
Begin period cash flow 273.74M 99.70M 142.14M 133.54M 80.09M
End period cash flow 257.84M 273.74M 99.70M 142.14M 133.54M
Total cash from operating activities -131.56M -79.13M -64.36M -50.14M -45.82M
Issuance of capital stock 258.86M 250.00M 0.00M 42.30M 81.92M
Depreciation 0.00M 0.53M 3.16M 3.18M 2.62M
Other cashflows from financing activities 267.27M -7.66M 0.16M 16.75M 16.90M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 9.44M -3.34M 6.28M -3.78M 1.88M
Stock based compensation 20.10M 16.91M 15.49M 13.71M 42.72M
Other non cash items 22.70M 15.45M 8.46M -6.45M 1.16M
Free cash flow -131.56M -79.13M -64.36M -50.14M -45.82M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
DFTX
Definium Therapeutics, Inc.		 1.30
3.92%		 34.58 - - - 6.95
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

One World Trade Center, New York, NY, United States, 10007

212 220 6633

https://definiumtx.com

105

Name Title Year Born
Mr. Robert Barrow CEO & Director 1990
Mr. Mark R. Sullivan J.D. Chief Legal Officer & Corporate Secretary 1971
Dr. Daniel Rollings Karlin M.A., M.D. Chief Medical Officer 1981
Dr. Scott M. Freeman M.D. Co-Founder & Clinical Advisor 1957
Mr. Leonard Latchman Co-Founder NA
Ms. Brandi L. Roberts CPA, M.B.A. Chief Financial Officer 1974
Mr. Peter Mack Senior Vice President of Pharmaceutical Development & Operations NA
Ms. Gitanjali Jain Ogawa VP & Head of Investor Relations NA
Ms. Beth Calitri Vice President of Corporate Communications NA
Ms. Stephanie Fagan M.S. Chief Corporate Affairs Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…